SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9495)4/1/1999 12:26:00 PM
From: aknahow  Respond to of 17367
 
Cacaito, sorry your wrong. No competitor! <g> XOMA makes this protein. This is the explanation of why the P III trial is continuing. They want to convince a potential buyer of the rights to Thaumatin that there is a big market for it.

Thaumatin, a control cationic protein

This is their sweetner. FEMA/GRAS approved. See products pipeline.



To: Cacaito who wrote (9495)4/1/1999 12:38:00 PM
From: aknahow  Respond to of 17367
 
Cacaito, kidding, serious, crazy, rambling but XOMA BPI patents always point out how always there is a potential for it to work better in vivo than in vitro. They always also say they are not 100% sure of how it works. How sure is anyone Thaumatin really is a placebo?

If one does not know how BPI works how the heck do they know how Thaumatin doesn't work?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News